Abstract
The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
Keywords: Photodynamic therapy, photosensitizers, upconversion nanoparticles.
Current Pharmaceutical Design
Title:Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology
Volume: 22 Issue: 46
Author(s): Carsten Lange and Patrick J. Bednarski
Affiliation:
Keywords: Photodynamic therapy, photosensitizers, upconversion nanoparticles.
Abstract: The combined use of a photosensitizing agent, light and dioxygen for the treatment of diseases has become known as photodynamic therapy (PDT) and was first discovered more than one hundred years ago. Over the years, PDT has proven its potential for the treatment of malignant and non-malignant lesions in addition to classical cancer therapy in numerous clinical studies, but application as a routine method is still limited. In this review, the development of modern PDT since the beginning of the twentieth century is briefly portrayed. The underlying mechanisms of phototoxicity are explained, and the requirements for ideal photosensitizers (PS) are underlined. Selected PS are introduced and examples of some of the many attempts made at the optimization of PDT by developing new PS with improved chemical and phototoxic properties, are reviewed. Promising 3rd generation PS are introduced and newer approaches to increasing tumor selectivity and efficacy of PDT, such as with nanoparticles, are discussed.
Export Options
About this article
Cite this article as:
Lange Carsten and Bednarski J. Patrick, Photosensitizers for Photodynamic Therapy: Photochemistry in the Service of Oncology, Current Pharmaceutical Design 2016; 22 (46) . https://dx.doi.org/10.2174/1381612822666161124155344
DOI https://dx.doi.org/10.2174/1381612822666161124155344 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Drugs for AIDS
Mini-Reviews in Medicinal Chemistry Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Oral Infection and Vascular Disease
Vascular Disease Prevention (Discontinued) The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Clinical Grade Stem Cell Culture
Recent Patents on Regenerative Medicine Resilience to Alzheimer's Disease: The Role of Physical Activity
Current Alzheimer Research Multi-Targeted Natural Products Evaluation Based on Biological Activity Prediction with PASS
Current Pharmaceutical Design Childhood and Adulthood Rural Residence Increases the Risk of Dementia: NEDICES Study
Current Alzheimer Research Current Insights Into Inositol Isoforms, Mediterranean and Ketogenic Diets for Polycystic Ovary Syndrome: From Bench to Bedside
Current Pharmaceutical Design Experimental Diabetes Mellitus Down-Regulates Large-Conductance Ca2+- Activated K+ Channels in Cerebral Artery Smooth Muscle and Alters Functional Conductance
Current Neurovascular Research Endocrine Therapies and QTc Prolongation
Current Drug Safety Next Steps in Alzheimers Disease Research: Interaction between Epidemiology and Basic Science
Current Alzheimer Research Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Oxidative Stress in Polycystic Ovary Syndrome
Current Pharmaceutical Design Protein kinases and the Hypoxia-Inducible Factor-1, two switches in angiogenesis
Current Pharmaceutical Design Haptoglobin Polymorphism and Lacunar Stroke
Current Neurovascular Research